Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis

被引:0
作者
Chen, Bai-lin [1 ,2 ]
Huang, Shan [1 ]
Dong, Xiao-wan [1 ,2 ]
Wu, Dou-dou [1 ,2 ]
Bai, Yan-ping [2 ]
Chen, Yuan-yuan [3 ]
机构
[1] Beijing Univ Chinese Med, Beijing, Peoples R China
[2] China Japan Friendship Hosp, Natl Ctr Integrat Med, Beijing, Peoples R China
[3] Beijing Hosp Integrated Tradit Chinese & Western M, Beijing 100039, Peoples R China
基金
中国国家自然科学基金;
关键词
Janus kinase inhibitors; acne; dermatologic; systematic review; network meta-analysis; SEVERE ATOPIC-DERMATITIS; DOUBLE-BLIND; RUXOLITINIB CREAM; EFFICACY; PLACEBO; SAFETY; ADOLESCENTS; PHASE-3; ADULTS; UPADACITINIB;
D O I
10.1080/09546634.2024.2397477
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The occurrence of acne in patients treated with Janus kinase (JAK) inhibitors for skin diseases is a potential issue, which may reduce treatment adherence. Purpose: To systematically analyzes randomized clinical trials (RCTs) of JAK inhibitors in dermatological indications for the risk of acne as an adverse event. Methods: A meta-analysis of odds ratios (ORs) for acne incidence was conducted. Data were quantitatively synthesized using random-effects meta-analysis. Surface under the cumulative ranking curve (SUCRA) values representing the relative ranking probabilities of treatments were obtained. Analyses were performed using R statistical software version 4.4.0. Results: A total of 11,396 patients were included from 24 studies. The incidence of acne for JAK inhibitors was ranked according to the SUCRA as follows: JAK1 inhibitors > TYK2 inhibitors > combined JAK1 and JAK2 inhibitors > combined JAK1 and TYK2 inhibitors > JAK3 + TEC inhibitors > pan-JAK inhibitors. ORs were higher for longer durations of drug use and larger dosages. Subgroup analyses by disease indication revealed increased ORs for psoriasis (5.52 [95% CI, 1.39-21.88]), vitiligo (4.15 [95% CI, 1.27-13.58]), alopecia areata (3.86 [95% CI, 1.58-9.42]), and atopic dermatitis (2.82 [95% CI, 1.75-4.54]). The use of JAK inhibitors in patients with systemic lupus erythematosus (SLE) may not significantly increase the incidence of acne. Conclusions: There are higher rates of acne following treatment with JAK inhibitors for dermatologic indications, particularly with longer durations and larger dosages. Pan-JAK inhibitors exhibit the lowest incidence of acne.
引用
收藏
页数:8
相关论文
共 50 条
[21]   Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis [J].
Alves, Carlos ;
Penedones, Ana ;
Mendes, Diogo ;
Marques, Francisco Batel .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (04) :830-838
[22]   Switching From Dupilumab to Tralokinumab or Janus Kinase Inhibitors in Cases of Ocular and/or Facial Adverse Events in Patients With Atopic Dermatitis: A Multicenter Retrospective Study [J].
Beyrouti, Alexandre ;
Deuze, Juliette ;
Fontas, Eric ;
Foureau, Aurore ;
Barbarot, Sebastien ;
Aubert, Helene ;
Bernier, Claire ;
Le Moigne, Marie ;
Passeron, Thierry ;
Boukari, Feriel ;
Garnier, Margaux ;
Jachiet, Marie ;
Tetart, Florence ;
Seneschal, Julien ;
Toussaiant, Clementine ;
Mah, Emmanuel ;
Leleu, Camille ;
Regnault, Marie Masson ;
Pasteur, Justine ;
Nosbaum, Audrey ;
Badaoui, Antoine ;
Fougerousse, Anne-Claire ;
Pralong, Pauline ;
Viguier, Manuelle ;
Droitcourt, Catherine ;
Abasq, Claire ;
Mallet, Phanie ;
Mallet, Stephaine ;
Raison-Peyron, Nadia ;
Staumont-Sall, Delphine ;
Hubiche, Thomas ;
Grp Recherche Atopique GREAT Res Grp .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2025, 13 (02) :353-360
[23]   Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo [J].
Pranic, Shelly ;
Pulumati, Anika ;
Vukovic, Dubravka .
SYSTEMATIC REVIEWS, 2024, 13 (01)
[24]   Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis [J].
Yang, Huibin ;
An, Ting ;
Zhao, Yuxuan ;
Shi, Xiaojing ;
Wang, Bangmao ;
Zhang, Qingyu .
ANNALS OF MEDICINE, 2025, 57 (01)
[25]   Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis [J].
Chen, Qianyu ;
Cui, Lian ;
Chen, Zeyu ;
Gao, Yunlu ;
Shi, Yuling .
HELIYON, 2023, 9 (11)
[26]   The efficacy and safety of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and meta-analysis [J].
Chen, Jingsi ;
Cheng, Jun ;
Yang, Huan ;
Tu, Wei ;
Zhang, Yan ;
Luo, Xiaoyan ;
Wang, Hua .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (02) :495-496
[27]   Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis [J].
Xiong, Grace ;
Yu, Eric ;
Heung, Martin ;
Yang, Jaehyeong ;
Lowe, Megan ;
Abu-Hilal, Mohannad .
JAAD INTERNATIONAL, 2025, 19 :1-9
[28]   Use of systemic Janus kinase inhibitors for dermatologic indications in the elderly: A retrospective study of 67 cases [J].
Hren, M. Grace ;
Khattri, Saakshi .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (04) :816-819
[29]   Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis [J].
Li, Chenyang ;
Sun, Xun ;
Zhao, Kun ;
Meng, Fanxiang ;
Li, Lin ;
Mu, Zhenzhen ;
Han, Xiuping .
DERMATOLOGY, 2022, 238 (04) :725-735
[30]   Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis [J].
Jiang, Yi ;
Zhang, Ning ;
Pang, Hailin ;
Gao, Xiaobo ;
Zhang, Helong .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 :293-302